{"schema_version":"alpha-company-profile-public-v2","slug":"q32-bio-inc","canonical_url":"https://registry.alpha.ac/companies/q32-bio-inc","published_on":"2026-09-13T04:46:26.757159+00:00","last_reviewed_on":"2026-09-13T04:46:26.757159+00:00","identity":{"legal_name":"Q32 Bio Inc.","display_name":"Q32 Bio Inc.","headline":"Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory…","description":"Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished it","ten_second_view":"This Company Profile publishes only Alpha's canonical identity and evidence-backed public leadership records. Unavailable fields are not inferred.","legal_form":"Not publicly asserted","incorporation":"Not publicly asserted","headquarters":"US","headquarters_address":{"locality":"Not publicly asserted","region":null,"country":"US"},"operating_presence":["US"],"website":"","cik":"0001661998","logo":"https://cdn.brandfetch.io/ticker/qttb/theme/dark/fallback/404/type/logo?c=1idgAB6rG5KFT5I7q5w","logo_source":"brandfetch","profile_mark":{"src":"https://cdn.brandfetch.io/ticker/qttb/theme/dark/fallback/404/type/logo?c=1idgAB6rG5KFT5I7q5w","alt":"Q32 Bio Inc. logo","width":256,"height":256,"source":"brandfetch"}},"entity_status":{"ownership_type":"unknown","listing_status":"listed","label":"Public listing published","explanation":"The canonical public record includes at least one active security listing.","source_id":"alpha-canonical-company-record","reviewed_on":"2026-09-13T04:46:26.757159+00:00"},"security_listings":[{"ticker":"QTTB","exchange":"NASDAQ","exchange_display":"NASDAQ","mic":"XNAS","currency":"Unavailable","security_type":"equity","listing_status":"active","is_primary":true,"source_id":"alpha-canonical-company-record"}],"market_data":{"availability":"unavailable","endpoint":null,"source_label":null,"explanation":"Market data is not published in this Company Profile."},"profile_tags":["Canonical identity","Public leadership"],"trust_summary":"Canonical identity published; broader company intelligence is not asserted.","facts":[{"label":"Legal name","value":"Q32 Bio Inc.","source_id":"alpha-canonical-company-record"},{"label":"Country","value":"US","source_id":"alpha-canonical-company-record"},{"label":"Sector","value":"Healthcare","source_id":"alpha-canonical-company-record"},{"label":"Industry","value":"Biotechnology","source_id":"alpha-canonical-company-record"}],"operating_model":{"eyebrow":"Operating record","title":"Published operating structure","units":[]},"governance":{"summary":"Only current, confirmed leadership roles with public evidence are included in the canonical projection.","boundary":"Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.","disclosures":[]},"alpha_opinion":{"status":"Not published","label":"No Alpha opinion published","explanation":"This identity record is not an Alpha rating, score, or investment opinion."},"report":{"status":"Not published","label":"No governed report published","explanation":"No governed company report is attached to this profile.","href":null},"actions":[],"related_records":[],"evidence":[{"id":"alpha-canonical-company-record","label":"Alpha canonical company public projection","href":"/api/public/companies/q32-bio-inc","source_type":"canonical_identity","supports":["Company identity","Published leadership","Entity status boundary"],"status":"published","reviewed_on":"2026-09-13T04:46:26.757159+00:00"}],"permissions":[{"label":"Public retrieval","allowed":true},{"label":"Agent retrieval","allowed":true},{"label":"Redistribution","allowed":false},{"label":"Model training","allowed":false},{"label":"Relationship pathfinding","allowed":false},{"label":"Direct contact","allowed":false}],"limitations":["Only explicitly published canonical company identity and current confirmed public roles are included.","Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.","Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.","This Company Profile is an identity and evidence record, not an Alpha rating."],"trust":{"schema_version":"alpha-profile-trust-v1","verification":{"schema_version":"alpha-verification-states-v1","state":"source_reported","identity_ownership":"unclaimed","assurance_level":null,"claim_state_counts":{"source_reported":14,"corroborated":0,"alpha_verified":0,"disputed":0,"superseded":0},"derivation":"claim_states+identity_ownership","summary":"Published claims are reported by public sources; none is Alpha verified. Profile ownership is unclaimed."},"aggregation":{"schema_version":"alpha-claim-aggregation-v1","published_claim_count":14,"under_review_claim_count":1,"owner_supplied_claim_count":0,"evidence_record_count":2,"distinct_source_count":2,"conflicts":[],"conflict_count":0,"headline_conflict_count":0,"internal_review_conflict_count":0,"contradiction_types":[],"headline_conflict_types":[],"verification":{"schema_version":"alpha-verification-states-v1","state":"source_reported","identity_ownership":"unclaimed","assurance_level":null,"claim_state_counts":{"source_reported":14,"corroborated":0,"alpha_verified":0,"disputed":0,"superseded":0},"derivation":"claim_states+identity_ownership","summary":"Published claims are reported by public sources; none is Alpha verified. Profile ownership is unclaimed."},"coverage":{"schema_version":"alpha-coverage-metric-v1","published_claims":14,"corroborated_claims":0,"sources":2,"distinct_sources":2,"role_claims":0,"last_reviewed_at":"2026-09-13T04:46:26.757159+00:00","observed_at":"2026-09-13T04:46:26.757159+00:00","freshness_days":0}},"rights":{"public_retrieval":"allowed","agent_retrieval":"allowed","redistribution":"not_granted","model_training":"not_granted","commercial_use":"not_specified","relationship_pathfinding":"not_granted","direct_contact":"not_granted"}},"projection":{"schema_version":"alpha-profile-projection-v5","entity":{"kind":"company","slug":"q32-bio-inc","canonical_url":"https://registry.alpha.ac/companies/q32-bio-inc"},"publication":{"published_at":"2026-09-13T04:46:26.757159+00:00","last_reviewed_at":"2026-09-13T04:46:26.757159+00:00","as_of":"2026-09-13T04:46:26.757159+00:00"},"representations":{"html":{"href":"https://registry.alpha.ac/companies/q32-bio-inc","media_type":"text/html"},"json":{"href":"https://registry.alpha.ac/api/public/companies/q32-bio-inc","media_type":"application/json"},"markdown":{"href":"https://registry.alpha.ac/companies/q32-bio-inc.md","media_type":"text/markdown"},"structured_data":{"embedded":true,"media_type":"application/ld+json"},"share_image":null},"permissions":{"public_retrieval":true,"agent_retrieval":true,"redistribution":false,"model_training":false,"relationship_pathfinding":false,"direct_contact":false}},"canonical_profile":{"schema_version":"alpha-company-profile-public-v1","slug":"q32-bio-inc","canonical_url":"https://registry.alpha.ac/companies/q32-bio-inc","as_of":"2026-09-13T04:46:26.757159+00:00","last_reviewed_at":"2026-09-13T04:46:26.757159+00:00","identity":{"legal_name":"Q32 Bio Inc.","display_name":"Q32 Bio Inc.","description":"Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished it","jurisdiction":null,"country":"US","sector":"Healthcare","industry":"Biotechnology","website":null,"website_provenance":null,"logo_url":null,"logo_media":null,"status":"active","cik":"0001661998","entity_subtype":null,"legal_entity_status":null},"security_listings":[{"mic":"XNAS","ticker":"QTTB","currency":null,"exchange":"NASDAQ","sort_key":0,"valid_to":null,"confidence":0.95,"is_primary":true,"listing_id":"14b60615-1daa-4b5b-9b3c-2a526155664c","source_url":"https://www.sec.gov/files/company_tickers_exchange.json","valid_from":null,"observed_at":"2026-07-11T00:28:32+00:00","source_name":"sec_company_tickers_exchange","source_tier":1,"exchange_name":"NASDAQ","security_type":"equity","listing_status":"active","last_checked_at":"2026-09-02T01:48:40.989053+00:00"}],"market_data":{"availability":"unavailable","endpoint":null,"source_label":null,"explanation":"Market observations are unpublished. Listing identity remains available from the governed source set."},"index_memberships":[],"index_membership_history":[],"index_membership_contract":{"schema_version":"alpha-index-membership-public-v1","as_of_date":"2026-09-13","tracked_universe_complete":false,"permissions":{"public_retrieval":true,"agent_retrieval":false,"redistribution":false,"model_training":false},"limitations":["Only source-backed memberships with an explicit public redistribution basis are returned.","Absence from Alpha tracked indices does not establish absence from every market index.","Provider announcements and effective membership are represented as distinct states.","Alpha AI 100 is not published as a current public index membership."]},"leadership":{"board":[{"person_slug":"arthur-o-tzianabos-ph-d","display_name":"Arthur O. Tzianabos, Ph.D.","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2016-01-01","end_date":null,"verification_status":"confirmed","confidence":0.85,"evidence":{"document_title":"Q32 Bio Inc. DEF 14A 2025-04-29","source_url":"https://www.sec.gov/Archives/edgar/data/1661998/000095017025059558/qttb-20250429.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2025-04-29","last_checked_at":"2026-04-28T23:37:00.299+00:00"},"headshot_url":null},{"person_slug":"bill-lundberg-m-d","display_name":"Bill Lundberg, M.D.","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2024-01-01","end_date":null,"verification_status":"confirmed","confidence":0.85,"evidence":{"document_title":"Q32 Bio Inc. DEF 14A 2025-04-29","source_url":"https://www.sec.gov/Archives/edgar/data/1661998/000095017025059558/qttb-20250429.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2025-04-29","last_checked_at":"2026-04-28T23:37:00.299+00:00"},"headshot_url":null},{"person_slug":"david-grayzel-m-d","display_name":"David Grayzel, M.D.","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2024-01-01","end_date":null,"verification_status":"confirmed","confidence":0.85,"evidence":{"document_title":"Q32 Bio Inc. DEF 14A 2025-04-29","source_url":"https://www.sec.gov/Archives/edgar/data/1661998/000095017025059558/qttb-20250429.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2025-04-29","last_checked_at":"2026-04-28T23:37:00.299+00:00"},"headshot_url":null},{"person_slug":"diyong-xu","display_name":"Diyong Xu","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2024-01-01","end_date":null,"verification_status":"confirmed","confidence":0.85,"evidence":{"document_title":"Q32 Bio Inc. DEF 14A 2025-04-29","source_url":"https://www.sec.gov/Archives/edgar/data/1661998/000095017025059558/qttb-20250429.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2025-04-29","last_checked_at":"2026-04-28T23:37:00.299+00:00"},"headshot_url":null},{"person_slug":"isaac-manke-ph-d","display_name":"Isaac Manke, Ph.D.","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2024-01-01","end_date":null,"verification_status":"confirmed","confidence":0.85,"evidence":{"document_title":"Q32 Bio Inc. DEF 14A 2025-04-29","source_url":"https://www.sec.gov/Archives/edgar/data/1661998/000095017025059558/qttb-20250429.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2025-04-29","last_checked_at":"2026-04-28T23:37:00.299+00:00"},"headshot_url":null},{"person_slug":"jodie-morrison","display_name":"Jim Morrison","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":false,"start_date":"2024-01-01","end_date":null,"verification_status":"confirmed","confidence":0.85,"evidence":{"document_title":"Q32 Bio Inc. DEF 14A 2025-04-29","source_url":"https://www.sec.gov/Archives/edgar/data/1661998/000095017025059558/qttb-20250429.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2025-04-29","last_checked_at":"2026-04-28T23:37:00.299+00:00"},"headshot_url":null},{"person_slug":"kathleen-laporte","display_name":"Kathleen LaPorte","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2024-01-01","end_date":null,"verification_status":"confirmed","confidence":0.85,"evidence":{"document_title":"Q32 Bio Inc. DEF 14A 2025-04-29","source_url":"https://www.sec.gov/Archives/edgar/data/1661998/000095017025059558/qttb-20250429.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2025-04-29","last_checked_at":"2026-04-28T23:37:00.299+00:00"},"headshot_url":null},{"person_slug":"mark-iwicki","display_name":"Mark Iwicki","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2024-01-01","end_date":null,"verification_status":"confirmed","confidence":0.85,"evidence":{"document_title":"Q32 Bio Inc. DEF 14A 2025-04-29","source_url":"https://www.sec.gov/Archives/edgar/data/1661998/000095017025059558/qttb-20250429.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2025-04-29","last_checked_at":"2026-04-28T23:37:00.299+00:00"},"headshot_url":null},{"person_slug":"mary-thistle-2","display_name":"Mary Thistle","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2018-01-01","end_date":null,"verification_status":"confirmed","confidence":0.85,"evidence":{"document_title":"Q32 Bio Inc. DEF 14A 2025-04-29","source_url":"https://www.sec.gov/Archives/edgar/data/1661998/000095017025059558/qttb-20250429.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2025-04-29","last_checked_at":"2026-04-28T23:37:00.299+00:00"},"headshot_url":null}],"executives":[],"coverage":{"schema_version":"alpha-leadership-coverage-v1","board_roster_scope":"def_14a_current_directors","executive_roster_scope":"NOT_ASSERTED","neo_set_status":"NOT_ASSERTED","board_roster_complete":false,"neo_set_complete":false,"notes":["Empty executives is NOT_ASSERTED, not a complete named-executive-officer set.","Form 4 occupancy is not a DEF 14A board.","Unconfirmed current sec_proxy DEF 14A directors may project. Confirmed is not required.","Unconfirmed current executives with first-party issuer evidence (source_url + effective date) may project.","Company-page directors do not require people.public_profile_enabled.","Completeness compares the latest first-party roster with the public projection; a source older than 180 days is STALE.","Do not remap HONA to HON 0000773840. Do not merge XOM 0000034088 with 0002115436.","Person match is projection-only. Name-only Person merges are forbidden."],"completeness":{"reasons":["NO_LEADERSHIP_SOURCE"],"board_completeness":"NOT_REVIEWED","completeness_schema":"alpha-leadership-completeness-v1","executive_team_completeness":"NOT_REVIEWED"},"parser_bleed_excluded":true,"former_titles_excluded":true,"identity_merge_forbidden":true,"form4_occupancy_is_not_board":true}},"permissions":{"classification":"open_public_projection","public_retrieval":true,"agent_retrieval":true,"redistribution":false,"model_training":false,"relationship_pathfinding":false,"direct_contact":false},"limitations":["Only explicitly published canonical company identity and current confirmed public roles are included.","Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.","Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.","This Company Profile is an identity and evidence record, not an Alpha rating."],"structured_data":{"@context":["https://schema.org",{"alpha":"https://alpha.ac/ns/","indexMembership":"alpha:indexMembership","indexProvider":"alpha:indexProvider","indexMembershipStatus":"alpha:indexMembershipStatus","indexEffectiveDate":"alpha:indexEffectiveDate","indexAnnouncementDate":"alpha:indexAnnouncementDate","indexRemovalDate":"alpha:indexRemovalDate","lastVerifiedAt":"alpha:lastVerifiedAt","verificationStatus":"alpha:verificationStatus","evidence":"alpha:evidence"}],"@type":"ProfilePage","@id":"https://registry.alpha.ac/companies/q32-bio-inc#profile","url":"https://registry.alpha.ac/companies/q32-bio-inc","dateModified":"2026-09-13T04:46:26.757159+00:00","mainEntity":{"@type":"Organization","@id":"https://registry.alpha.ac/companies/q32-bio-inc#organization","legalName":"Q32 Bio Inc.","name":"Q32 Bio Inc.","description":"Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished it","url":"https://registry.alpha.ac/companies/q32-bio-inc","addressCountry":"US","indexMembership":[],"member":[{"@type":"OrganizationRole","roleName":"Director","startDate":"2016-01-01","member":{"@type":"Person","name":"Arthur O. Tzianabos, Ph.D.","url":"https://registry.alpha.ac/people/arthur-o-tzianabos-ph-d"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2024-01-01","member":{"@type":"Person","name":"Bill Lundberg, M.D.","url":"https://registry.alpha.ac/people/bill-lundberg-m-d"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2024-01-01","member":{"@type":"Person","name":"David Grayzel, M.D.","url":"https://registry.alpha.ac/people/david-grayzel-m-d"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2024-01-01","member":{"@type":"Person","name":"Diyong Xu","url":"https://registry.alpha.ac/people/diyong-xu"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2024-01-01","member":{"@type":"Person","name":"Isaac Manke, Ph.D.","url":"https://registry.alpha.ac/people/isaac-manke-ph-d"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2024-01-01","member":{"@type":"Person","name":"Jim Morrison","url":"https://registry.alpha.ac/people/jodie-morrison"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2024-01-01","member":{"@type":"Person","name":"Kathleen LaPorte","url":"https://registry.alpha.ac/people/kathleen-laporte"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2024-01-01","member":{"@type":"Person","name":"Mark Iwicki","url":"https://registry.alpha.ac/people/mark-iwicki"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2018-01-01","member":{"@type":"Person","name":"Mary Thistle","url":"https://registry.alpha.ac/people/mary-thistle-2"}}]},"mainEntityOfPage":"https://registry.alpha.ac/companies/q32-bio-inc"}},"canonical_source":"aegis_canonical"}